Memo Therapeutics

Memo Therapeutics, develops MemoMAB a disruptive technology for the mining of human antibodyomes for unbiased discovery of therapeutic antibodies and targets.

  • Stage Product In Development
  • Industry Biotechnology
  • Location Zurich, Switzerland
  • Currency CHF
  • Founded November 2012
  • Employees 2

Only investors on Gust who have been granted access can view this content.

Interested in this startup? Sign In or Sign Up to request more information.

Starting a startup?

Join the world's largest startup network for guidance, tools, and fundraising opportunities.

Get Started for Free